Get the Stockscreener App
1.49
0.00%
0.00
Curis Inc stock is traded at $1.49, with a volume of 46,381.
It is up +0.00% in the last 24 hours and down -10.24% over the past month.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$1.49
Open:
$1.49
24h Volume:
46,381
Relative Volume:
0.66
Market Cap:
$18.62M
Revenue:
$11.41M
Net Income/Loss:
$-38.92M
P/E Ratio:
-0.3052
EPS:
-4.8828
Net Cash Flow:
$-30.46M
1W Performance:
-7.45%
1M Performance:
-10.24%
6M Performance:
-29.38%
1Y Performance:
-65.19%
1-Day Range:
$1.48
$1.524
1-Week Range:
$1.46
$1.65
52-Week Range:
$1.02
$5.00
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
1.49 | 18.62M | 11.41M | -38.92M | -30.46M | -4.8828 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
Applying Wyckoff theory to Curis Inc. stockWeekly Profit Recap & AI Driven Price Forecasts - newser.com
Is Curis Inc. (CUS0) stock a top hedge fund pickFed Meeting & Daily Risk Controlled Trade Plans - newser.com
How Curis Inc. stock performs in high volatility marketsJuly 2025 Snapshot & Low Drawdown Momentum Trade Ideas - newser.com
Detecting support and resistance levels for Curis Inc.Market Activity Recap & Real-Time Stock Entry Alerts - newser.com
Is Curis Inc. stock attractive for income investorsJuly 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com
Can a trend reversal in Curis Inc. lead to recoveryMarket Growth Review & Low Volatility Stock Recommendations - newser.com
How Curis Inc. stock responds to policy changes2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
Will Curis Inc. (CUS0) stock gain from lower interest ratesEarnings Growth Summary & Free Community Supported Trade Ideas - newser.com
Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025 - Barchart.com
Can Curis Inc. (CUS0) stock sustain breakout momentum2025 Market Overview & Fast Exit/Entry Strategy Plans - newser.com
Curis (NASDAQ: CRIS) to report Q3 2025 results; investor call at 4:30 p.m. ET - Stock Titan
What analysts say about Curis Inc stockREITs Market Trends & Free Fastest Return On Investment - earlytimes.in
Curis Stock Fell 7.7% in a Month, What Now? - Trefis
How buybacks impact Curis Inc. stock valueMarket Growth Report & Free Real-Time Volume Trigger Notifications - Fundação Cultural do Pará
Is Curis Inc. (CUS0) stock included in top ETFs2025 Trade Ideas & Accurate Buy Signal Notifications - newser.com
Can Curis Inc. stock resist sector downturnsJuly 2025 Patterns & Stepwise Entry and Exit Trade Signals - fcp.pa.gov.br
Should You Invest in Ducon Infratechnologies Limited Before Its Next Earnings ReportSwing Trading Ideas & Get Alerts on Stocks Set to Skyrocket - earlytimes.in
Curis Inc.’s Promising Study on Emavusertib for AML and MDS: A Potential Game-Changer - TipRanks
Curis Inc. Advances Lymphoma Treatment with Emavusertib Study - TipRanks
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):